ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma
ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.
ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.
PURPOSE Human epidermal growth factor receptor 2 (HER2) is an effective therapeutic target in breast and gastric and gastroesophageal junction cancers. However, less is known…
PURPOSE To study whether BRAF V600 mutations in non–small-cell lung cancer (NSCLC) may indicate sensitivity to the BRAF inhibitor vemurafenib, we included a cohort of…
Purpose Parallel activation of the phosphatidylinositol 3-kinase–mammalian target of rapamycin pathway represents a mechanism of primary and acquired resistance to BRAF-targeted therapy, but the two…
One to two percent of non–small-cell lung cancers (NSCLCs) harbor ROS1 gene rearrangements. 1 – 3 ROS1 gene rearrangement leads to constitutive activation receptor tyrosine…
Solid pseudopapillary neoplasms (SPNs) of the pancreas are exocrine neoplasms that predominantly affect young females and are considered to have low malignant potential. Surgical resection…
Financial support: Jie Wu, Jie Wu Administrative support: Vivek Subbiah, Vivek Subbiah Provision of study materials or patients: Sireesha Yedururi, Vivek Subbiah, Sireesha Yedururi, Vivek…
Medullary thyroid cancer (MTC) is a neuroendocrine tumor that originates from the parafollicular cells (or C cells) of the thyroid gland and account s for…
(Bloomberg) — When Oracle Corp. spent $28 billion two years ago to acquire electronic-records company Cerner Corp., it promised a revolution in health care technology.…
We present a case showing intracranial efficacy of pemigatinib in pilocytic astrocytoma with FGFR1 N546K mutation
VivekSubbiah & colleagues delve into the @ASCO #TAPURStudy, shedding light on the importance of targeting ALL #BRAFAlterations, beyond V600E. (Re)-search continues, urging us to push…